Atorvastatin reduces the proadhesive and prothrombotic endothelial cell phenotype induced by cocaine and plasma from cocaine consumers in vitro

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 11, 2014, Pages 2439-2448

  Sáez, Claudia G ^a   Pereira Flores, Karla ^a   Ebensperger, Roberto ^a   Panes, Olga ^a   Massardo, Teresa ^b   Hidalgo, Patricia ^a   Mezzano, Diego ^a   Pereira, Jaime ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Atherosclerosis; Cocaine

Indexed keywords

ATORVASTATIN; CAVEOLIN 1; CD40 LIGAND; COCAINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROCOAGULANT; REACTIVE OXYGEN METABOLITE; SELECTIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE; VON WILLEBRAND ANTIGEN;

ARTICLE; BIOAVAILABILITY; BLOOD CLOTTING; CELL STIMULATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG ABUSE; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOLAYER CULTURE; PHENOTYPE; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE FREE PLASMA; UMBILICAL VEIN ENDOTHELIAL CELL; BLOOD; CELL ADHESION; CELL CULTURE; COCAINE DEPENDENCE; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PLASMA; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; CAVEOLIN 1; CELL ADHESION; CELLS, CULTURED; COCAINE; COCAINE-RELATED DISORDERS; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HUMANS; IN VITRO TECHNIQUES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; PLASMA; PYRROLES; REACTIVE OXYGEN SPECIES; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84911878271     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304535     Document Type: Article

References (42)

1. Kloner RA, Rezkalla SH. Cocaine and the heart. N Engl J Med. 2003;348:487-488.
2. Lange RA, Cigarroa RG, Yancy CW Jr, Willard JE, Popma JJ, Sills MN, McBride W, Kim AS, Hillis LD. Cocaine-induced coronary-artery vasoconstriction. N Engl J Med. 1989;321:1557-1562.
3. Lange RA, Hillis LD. Cardiov ascular complications of cocaine use. N Engl J Med. 2001;345:351-358.
4. Kendirci M,Pradhan L,Trost L,Gur S,Chandra S,Agrawal KC,Hellstrom WJ. Peripheral mechanisms of erectile dysfunction in a rat model of chronic cocaine use. Eur Urol. 2007;52:555-563.
5. Xiao D, Huang X, Xu Z, Yang S, Zhang L. Prenatal cocaine exposure differentially causes vascular dysfunction in adult offspring. Hypertension. 2009;53:937-943.
6. De Giorgi A, Fabbian F, Pala M, Bonetti F, Babini I, Bagnaresi I, Manfredini F, Portaluppi F, Mikhailidis DP, Manfredini R. Cocaine and acute vascular diseases. Curr Drug Abuse Rev. 2012;5:129-134.
7. Pradhan L, Mondal D, Chandra S, Ali M, Agrawal KC. Molecular analysis of cocaine-induced endothelial dysfun ction: role of endothelin-1 and nitric oxide. Cardiovasc Toxicol. 2008;8:161-171.
8. Sá ez CG, Olivares P, Pallavicini J, Panes O, Moreno N, Massardo T, Mezzano D, Pereira J. Increased number of circulating endothelial cells and plasma markers of endothelial damage in chronic cocaine users. Thromb Res. 2011;128:e18-e23.
9. Steffel J, Iseli S, Arnet C, Lüscher TF, Tanner FC. Cocaine unbalances endothelial tissue factor and tissue factor pathway inhibitor expression. J Mol Cell Cardiol. 2006;40:746-749.
10. He J, Yang S, Zhang L. Effects of cocaine on nitric oxide production in bovine coronary artery endothelial cells. J Pharmacol Exp Ther. 2005;314:980-986.
11. Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, Nishigaki I. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9:1057-1069.
12. Ruggeri ZM. Platelet and von Will ebrand factor interactions at the vessel wall. Hamostaseologie. 2004;24:1-11
13. Gawaz M. Platelets in the onset of atherosclerosis. Blood Cells Mol Dis. 2006;36:206-210.
14. Pereira J, Sá ez CG, Pallavicini J, Panes O, Pereira-Flores K, Cabreras MJ, Massardo T, Mezzano D. Platelet activation in chronic cocaine users: effect of short term abstinence. Platelets. 2011;22: 596-601.
15. Kugelmass AD, Oda A, Monahan K, Cabral C, Ware JA. Activation of human platelets by cocaine. Circulation. 1993;88:876-883.
16. Hobbs WE, Moore E E, Penkala RA, Bolgiano DD, Ló pez JA. Cocaine and specific cocaine metabolites induce von Willebrand factor release from endothelial cells in a tissue-specific manner. Arterioscler Thromb Vasc Biol. 2013;33:1230-1237.
17. Schulz C, Massberg S. Platelets in atherosclerosis and thrombosis. Handb Exp Pharmacol. 2012:111-133
18. Babelova A, Sedding DG, Brandes RP. Anti-atherosclerotic mechanisms of statin therapy. Curr Opin Pharmacol. 2013;13:260-264.
19. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives-. Circ J. 2010;74:818-826.
20. Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessels. 2008;23:249-256.
21. Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human athero sclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335-345
22. Herná ndez-Perera O, Pérez-Sala D, Navarro-Antolín J, Sánchez-Pascuala R, Hernández G, Dí az C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endotheli al cells. J Clin Invest. 1998;101:2711-2719.
23. Mulhaupt F, Matter CM, Kwak BR, Pelli G, Veillard NR, Burger F, Graber P, Lüscher TF, Mach F. Statins (HMG-CoA reductase inhib itors) reduce CD40 expression in human vascular cells. Cardiovasc Res. 2003;59:755-766.
24. Stach K, Nguyen XD, Lang S, Elmas E, Weiss C, Borggrefe M, Fischer J, Kälsch T. Simvast atin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand. Cardiol J. 2012;19:20-28.
25. Ota H,Eto M,Kano MR,Kahyo T,Setou M,Ogawa S,Iijima K,Akishita M,Ouchi Y. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol. 2010;30:2205-2211.
26. Sikora J, Kostka B, Marczyk I, Krajewska U, Cha?ubi?ski M, Broncel M. Effect of statins on platelet function in patients with hyperlipidemia. Arch Med Sci. 2013;9:622-628.
27. Fish RJ, Yang H, Viglino C, Schorer R, Dunoyer-Geindre S, Kruithof EK. Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues. Biochem J. 2007;405:597-604.
28. Werle M, Schmal U, Hanna K, Kreuzer J. MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells. Cardiovasc Res. 2002;56:284-292.
29. Gawaz M, Neumann FJ, Dickfeld T, Koch W, Laugwitz KL, Adelsberger H, Langenbrink K, Page S, Neumeier D, Schömig A, Brand K. Activated platelets induce monocyte chemotactic protein-1 secretio n and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation. 1998;98:1164-1171.
30. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutt i N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 2000;80:1095-1100.
31. Han KH, Ryu J, Hong KH, Ko J, Pak YK, Kim JB, Park SW, Kim JJ. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation. 2005;111:1439-1447.
32. Schuepbach RA, Velez K, Riewald M. Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain. Blood. 2011;117:6338-6346.
33. Brox JH, Osterud B, Bjø rklid E, Fenton JW II. Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin and platelets. Br J Haematol. 1984;57:239-246.
34. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL. Leukocyte proteases cleave von W illebrand factor at or near the ADAMTS13 cleavage site. Blood. 2009;114:1666-1674.
35. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007;100:1673-1685.
36. Liu M, Yu Y, Jiang H, Zhang L, Zhang PP, Yu P, Jia JG, Chen RZ, Zou YZ, Ge JB. Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Acta Pharmacol Sin. 20 13;34:830-836.
37. Dhillon NK, Peng F, Bokhari S, Callen S, Shin SH, Zhu X, Kim KJ, Buch SJ. Cocaine-mediated alteration in tight junction protein expression and modulation of CCL2/CCR2 axi s across the blood-brain barrier: implications for HIV-dementia. J Neuroimmune Pharmacol. 2008;3:52-56.
38. Yao H, Yang Y, Kim KJ, Bethel-Brown C, Gong N, Funa K, Gendelman HE, Su TP, Wang JQ, Buch S. Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood. 2010;115:4951-4962.
39. Undas A, Brummel-Zie dins KE, Mann KG. Anticoagulant effects of statins and their clinical implications. Thromb Haemost. 2014;111:392-400.
40. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutarylcoenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 200 1;103:113-118.
41. Mineo C, Shaul PW. Regulation of eNOS in caveolae. Adv Exp Med Biol. 2012;729:51-62.
42. Wu K, Tian S, Zhou H, Wu Y. Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation. Biochem Pharmacol. 2013;85:1753-1760.